Viatris(VTRS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company reported total revenues of $14.3 billion, representing approximately 2% growth compared to 2024, excluding the impact of the India pack [4][21] - Adjusted EBITDA for 2025 was $4.2 billion, with adjusted EPS of $2.35 per share and free cash flow of $2.2 billion, excluding transaction-related costs [21][22] - For Q4 2025, total revenues were $3.7 billion, up 1% year-over-year, excluding the indoor impact [20] Business Line Data and Key Metrics Changes - The company achieved strong commercial performance across its global portfolio, with significant contributions from its cardiovascular portfolio in Greater China and competitive strength in Europe and emerging markets [20][21] - New product revenues are anticipated to contribute $450 million to $550 million in 2026, with growth expected in developed markets and emerging markets [23][24] Market Data and Key Metrics Changes - In Greater China, the company expects 3% year-over-year growth, driven primarily by cardiovascular products [25] - Emerging markets are projected to grow 6% year-over-year, supported by expansion in key markets like Turkey, Mexico, India, and Brazil [24] Company Strategy and Development Direction - The company aims to drive its base business through successful product launches and evolving its generics portfolio towards higher-margin products [6][7] - Strategic imperatives include fueling the innovative portfolio with late-stage and in-market growth assets, and modernizing operations for sustainable growth [6][7] - The company plans to deliver approximately $650 million in gross cost savings over three years, with $250 million earmarked for reinvestment in growth areas [5][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering a period of long-term sustainable growth beginning in 2026, with a focus on strong financial performance and commercial execution [4][8] - The company anticipates regulatory decisions for several product candidates in 2026, which are expected to support future performance [8][11] Other Important Information - A fire incident at the Nashik, India facility has temporarily suspended manufacturing, with operations expected to resume in April [26] - The company is focused on returning the JANZ segment to growth while managing pricing headwinds in certain Asian markets [24][25] Q&A Session Summary Question: Path to mid-single-digit revenue growth and confidence in approvals - Management indicated that the path to mid-single-digit growth involves a growing base business and upcoming product launches, with confidence in the six potential approvals this year [32][34] Question: Breakdown of $650 million savings and timing - The savings are expected to be phased over three years, with approximately 30% in 2026, 30% in 2027, and 40% in 2028 [33][38] Question: Cost cuts and India recovery assumptions - About 50% of the $650 million savings will come from headcount reductions, with less than 1% of India recovery included in the 2026 guidance [40][43] Question: Restructuring charges versus net savings - The company estimates that the one-time costs to achieve savings will be about 1 times the gross savings, with $250 million expected this year [47][49] Question: Fast-acting meloxicam market focus - The initial focus for fast-acting meloxicam will be on post-operative and operative acute pain management, targeting specialty physicians [52][54] Question: Regulatory pricing challenges in Japan - Japan faces mandatory price decreases impacting revenue and EBITDA, but new assets are expected to turn the business towards growth by 2028 [56][58]